Other
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital
West Pharmaceutical Services Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital increased by 2409.8% to $102.9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 103000.0%, from -$100K to $102.9M.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2024
Last reportedQ1 2026Apr 23, 2026
Metric ID:
other_increase_decrease_in_operating_capitalHistorical Data
5 periods
| Q1 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $34.6M | $100K | -$100K | $4.1M | $102.9M |
| QoQ Change | — | -99.7% | -200.0% | >999% | >999% |
| YoY Change | — | — | -100.3% | — | >999% |
Range-$100K – $102.9M
CAGR+197.4%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak2 quarters growth
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital?
- West Pharmaceutical Services (WST) reported adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital of $102.9M in Q1 2026.
- How has West Pharmaceutical Services's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital changed year-over-year?
- West Pharmaceutical Services's adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital increased by 103000.0% year-over-year, from -$100K to $102.9M.